{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:55:24Z","timestamp":1784674524557,"version":"3.55.0"},"reference-count":41,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Chronic myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), are hematopoietic stem cell disorders characterized by increased proliferation of mature myeloid cells, a chronic inflammatory state, and high cardiovascular risk. The diagnostic and therapeutic landscape in the field of MPNs is rapidly evolving. Therefore, it is important to assess the behavior of physicians involved in the management of MPN patients to gain insight into how they embrace the current diagnostic and treatment landscape in real-life settings. Methods: An online anonymous survey consisting of 50 questions regarding their MPN practice and divided into four major domains (physician characteristics, diagnostic procedures, therapeutic decisions, and patient follow-up) was sent through the Croatian Cooperative Group for Hematologic Diseases\u2019 (KROHEM\u2019s) e-mailing list to all Croatian hematologists. Results: Thirty-one out of ninety adult hematologists (34.4% response rate) from KROHEM responded to this survey. There was a very high rate of self-proclaimed abidance to current international diagnostic and therapeutic recommendations, with no major differences among academic and community practices. However, some areas of uncertainty have been highlighted, especially in the frequency of cytogenetic and molecular testing, as well as very low implementation of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) questionnaire in everyday practice. Conclusions: This study provides an important snapshot of the current MPN practice in Croatia. Similar studies from other countries are needed to provide a more detailed overview of real-life MPN practice globally.<\/jats:p>","DOI":"10.3390\/jcm14051524","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:52:47Z","timestamp":1740394367000},"page":"1524","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-305X","authenticated-orcid":false,"given":"Ivan","family":"Krecak","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, General Hospital of Sibenik-Knin County, 22000 Sibenik, Croatia"},{"name":"Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia"},{"name":"University of Applied Sciences, 22000 Sibenik, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-2040","authenticated-orcid":false,"given":"Marko","family":"Lucijanic","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"Department of Scientific Research and Translational Medicine, University Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajko","family":"Kusec","sequence":"additional","affiliation":[{"name":"Division of Hematology, University Hospital Dubrava, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","article-title":"Normal life expectancy for polycythemia vera (PV) patients is possible","volume":"36","author":"Silver","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","article-title":"Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cncr.34103","article-title":"Improved survival of patients with myelofibrosis in the last decade: Single-center experience","volume":"128","author":"Masarova","year":"2022","journal-title":"Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: Genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.25555","article-title":"A GIMEMA Myeloproliferative Neoplasms Working Party initiative","volume":"94","author":"Loscocco","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00432-016-2209-1","article-title":"Characteristics and treatment of polycythemia vera patients in clinical practice: A multicenter chart review on 1476 individuals in Germany","volume":"142","author":"Eberhardt","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clml.2018.07.297","article-title":"Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns","volume":"19","author":"Habib","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.6004\/jnccn.2016.0133","article-title":"Practice Patterns in the Diagnosis and Treatment of Polycythemia Vera in the Post-JAK2 V617F Discovery Era","volume":"14","author":"Kander","year":"2016","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: Incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","article-title":"The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: A review","volume":"96","author":"Kc","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1038\/s41375-022-01673-3","article-title":"Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study on 1258 patients","volume":"36","author":"Mora","year":"2022","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.18440","article-title":"Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis","volume":"199","author":"Raya","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106905","DOI":"10.1016\/j.leukres.2022.106905","article-title":"Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis","volume":"119","author":"Lucijanic","year":"2022","journal-title":"Leuk. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/s41408-022-00743-0","article-title":"Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score","volume":"12","author":"Barbui","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms: Results from an international study on 442 patients","volume":"35","author":"Barbui","year":"2021","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41408-021-00566-5","article-title":"Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients","volume":"11","author":"How","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Baysal, M., Aksoy, E., Bedir, K.H., \u00d6zmen, D., Pat\u0131r, P., Demirci, U., Yaman, S., \u00d6zdemir, Z.N., G\u00fcrsoy, V., and Y\u0131ld\u0131zhan, E. (2024). Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): A multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology. J. Thromb. Thrombolysis.","DOI":"10.1007\/s11239-024-03043-5"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lee, J.Y., Lee, J.H., Park, W., Seo, J., Kang, M., Jung, E.H., Kim, S.-A., Suh, K.J., Kim, J.-W., and Kim, S.H. (2024). The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients. Cancer Res. Treat.","DOI":"10.4143\/crt.2024.738"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/17474086.2023.2174515","article-title":"Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: A systematic review","volume":"16","author":"Baysal","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ajh.27418","article-title":"Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial","volume":"99","author":"Rocca","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e70003","DOI":"10.1002\/hem3.70003","article-title":"Are we ready for disease modification in myeloproliferative neoplasms?","volume":"8","author":"Harrison","year":"2024","journal-title":"Hemasphere"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease Modification in Myelofibrosis: An Elusive Goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther. Adv. Hematol."},{"key":"ref_36","first-page":"35","article-title":"Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission [abstract]","volume":"136","author":"Zhao","year":"2021","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/ajh.27375","article-title":"Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-022-00639-z","article-title":"Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases","volume":"12","author":"Gangat","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.14798","article-title":"Cytogenetic findings in WHO-defined polycythaemia vera and their prognostic relevance","volume":"182","author":"Barraco","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: Findings from the MPN Landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:41:43Z","timestamp":1760028103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051524"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051524","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]}}}